Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.56 |
| ▸ | PREP | P48147 | 1/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250544 | 1.00 | DPP4 (0.56) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL14450652 | 0.86 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL8253205 | 0.86 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL8256353 | 0.86 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL5314581 | 0.80 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL3362068 | 0.80 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL26094394 | 0.80 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL858699 | 0.80 | DPP4 (0.59) | DPP4PREPDPP8DPP9DPP7 | |
| SCHEMBL10208862 | 0.79 | DPP4 (0.51) | DPP4PREPDPP8DPP9 | |
| SCHEMBL3398030 | 0.78 | DPP4 (0.57) | DPP4PREPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114380729-B | Preparation method of high-purity vildagliptin | 东北制药集团股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114380729-A | Preparation method of high-purity vildagliptin | 东北制药集团股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-108503571-B | Synthetic method of vildagliptin | 无锡科华生物科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-108658826-B | Method for preparing vildagliptin | 上海三牧化工技术有限公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-103435526-B | Synthesis method of vildagliptin | TIANJIN SUYAN MEDICINE SCIENCE & TECHNOLOGY CO LTD | 2015-05-06 | — | — | CN | disclosed |
| EP-1888562-B1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARM HOLDING (US) | 2014-06-18 | — | — | EP | disclosed |
| CN-103435526-A | Synthesis method of vildagliptin | TIANJIN SUYAN MEDICINE SCIENCE & TECHNOLOGY CO LTD | 2013-12-11 | — | — | CN | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8076330-B2 | Dipeptidyl peptidase-IV inhibitors | AMGEN INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553861-B2 | Dipeptidyl peptidase-IV inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2006116157-A2 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | DPP4 139/4885PREP 48/4885DPP8 121/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | DPP4 139/4885PREP 48/4885DPP8 121/4885 |
| US-20100009961-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITORS | DPP4, DPP3, DPP7 | DPP4 1/4885PREP 14/4885DPP8 5/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | DPP4 139/4885PREP 48/4885DPP8 121/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | DPP4 139/4885PREP 48/4885DPP8 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.